Samsung Biologics 3 Trillion Won Paid-in Capital Increase (삼성바이오 3조 유상증자)Compare →
- Daum 100%
- Naver DataLab 0%
Cross-confirmed by 2 sources — attention spread across platforms is more likely to be real.
Sample — 2 cross-checked sources · 5 snapshots (5-min interval)
Not on the board right now — here's the record of when it was.
Why it's trending
This is an actual headline, quoted as-is — never summarized or generated.
Related coverage
·
삼성바이오 3조 유상증자 first appeared on KoreaTrendBoard on August 28, 2026. It has been observed 5 times since, peaking at rank 3 with a score of 28.0. It was last seen on August 28, 2026. Being picked up by 2 separate sources means this is not one site's editorial choice — people are actually searching for it in several places.
Loading
This chart shows the last 14 days. Pro opens 180 days and lets you export the same data as CSV — one row per day with rank, score and source count. See what opens →
The full board on 2026-08-27 → · This week · Glossary
Picked up by: Daum, Naver DataLabReferenced from each site's publicly available rankings. No affiliation or partnership.
Want a heads-up when «삼성바이오 3조 유상증자» climbs again? It's free.
No signup form — your email is the account. One click to stop.
- 180-day history — the curve, not the moment
- Alerts — pinged within 5 minutes when your keyword moves
- API — ranks and scores straight into your report